Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab/Vibostolimab Co-Formulation
DRUG: Saline placebo
DRUG: Etoposide
DRUG: Cisplatin
BIOLOGICAL: Atezolizumab
DRUG: Carboplatin

Sponsor

Merck Sharp & Dohme LLC